Search research articles
Contact Us
Filters
Showing results (151-160 of 259) with videos related to
Page
of 26
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 17, 2026
Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial
Chiara Dauccia, Maria Alice Franzoi, Cristina Saura, et al.
JAMA Oncology
|
July 17, 2015
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado, Carsten Denkert, Christine Campbell, et al.
Oncotarget
|
September 4, 2015
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
Carlo Palmieri, Iain Rj Macpherson, Kelvin Yan, et al.
Breast (Edinburgh, Scotland)
|
February 6, 2026
Association between body mass index and risk of breast cancer according to breast cancer subtypes: A systematic review and meta-analysis
Chiara Dauccia, Marco Bruzzone, Luca Arecco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2012
Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study
Hatem A Azim, Niels Kroman, Marianne Paesmans, et al.
Breast (Edinburgh, Scotland)
|
June 12, 2026
Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials
Roberto Buonaiuto, Federica Pia Mangiacotti, Fabiola Giudici, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 5, 2021
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial
Samuel Martel, Matteo Lambertini, Dominique Agbor-Tarh, et al.
The Lancet. Oncology
|
February 19, 2013
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
Bernhard C Pestalozzi, Eileen Holmes, Evandro de Azambuja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2013
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
Sherene Loi, Nicolas Sirtaine, Fanny Piette, et al.
The Lancet. Oncology
|
November 4, 2021
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean
Gustavo Werutsky, Carlos H Barrios, Andres F Cardona, et al.
Page
of 26
Search research articles
Search
Showing results (151-160 of 259) with videos related to
Sort By:
Page
of 26
European Journal of Cancer (Oxford, England : 1990)
|
June 17, 2026
Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial
Chiara Dauccia, Maria Alice Franzoi, Cristina Saura, et al.
JAMA Oncology
|
July 17, 2015
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado, Carsten Denkert, Christine Campbell, et al.
Oncotarget
|
September 4, 2015
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
Carlo Palmieri, Iain Rj Macpherson, Kelvin Yan, et al.
Breast (Edinburgh, Scotland)
|
February 6, 2026
Association between body mass index and risk of breast cancer according to breast cancer subtypes: A systematic review and meta-analysis
Chiara Dauccia, Marco Bruzzone, Luca Arecco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2012
Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study
Hatem A Azim, Niels Kroman, Marianne Paesmans, et al.
Breast (Edinburgh, Scotland)
|
June 12, 2026
Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials
Roberto Buonaiuto, Federica Pia Mangiacotti, Fabiola Giudici, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 5, 2021
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial
Samuel Martel, Matteo Lambertini, Dominique Agbor-Tarh, et al.
The Lancet. Oncology
|
February 19, 2013
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
Bernhard C Pestalozzi, Eileen Holmes, Evandro de Azambuja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2013
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
Sherene Loi, Nicolas Sirtaine, Fanny Piette, et al.
The Lancet. Oncology
|
November 4, 2021
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean
Gustavo Werutsky, Carlos H Barrios, Andres F Cardona, et al.
Page
of 26